Navigation Links
Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
Date:11/16/2011

SAN MATEO, Calif., Nov. 16, 2011 /PRNewswire/ -- Nile Therapeutics, Inc. (OTCQB: NLTX), a biopharmaceutical company that develops novel therapeutics for heart failure patients, today announced top-line data from its recently completed Phase I clinical trial evaluating the pharmacokinetics (PK), pharmacodynamics (PD), safety and tolerability of subcutaneous bolus and subcutaneous infusion of cenderitide in patients with chronic heart failure. Nile is developing cenderitide as a 90-day outpatient treatment for heart failure patients following admission for acutely decompensated heart failure (ADHF), referred to as the "post-acute" treatment period.

The Phase I clinical trial was designed to understand the doses required to achieve pre-determined plasma levels of cenderitide when delivered through a subcutaneous infusion pump. The target cenderitide plasma levels were based on Nile's previous Phase 2 clinical trials in which cenderitide was delivered through continuous intravenous infusion. In Part A of the trial, 12 patients received two subcutaneous bolus injections of cenderitide.  In Part B of the trial, 34 patients received a 24-hour continuous subcutaneous infusion of either of two fixed doses of cenderitide or placebo. In Part C, 12 patients received a 24-hour continuous subcutaneous infusion of either a weight-based dose of cenderitide, or placebo. All infusions were delivered through subcutaneous pump technology of Medtronic, Inc. pursuant to the parties' February 2011 development collaboration agreement.

The top line results from the Phase 1 trial are as follows:

  • The primary end-point was met – cenderitide achieved target PK levels when delivered through Medtronic's subcutaneous pump technology;
  • 24 hour subcutaneous delivery of ceneritide through Medtronic's pump technology was well-tolerated, with no injection site irritation;
  • Subcutaneously delivered cenderitide has an acc
    '/>"/>

SOURCE Nile Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Nile Therapeutics Reports 2011 Third Quarter Financial Results
2. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
3. Orexigen® Therapeutics Reports Third Quarter Financial Results
4. Silence Therapeutics Provides Corporate and Development Update
5. Halozyme Therapeutics Reports Third Quarter 2011 Financial Results
6. Regado Biosciences, Inc. Presents Positive Efficacy and Safety Substudy Data from the Phase 2b RADAR Trial for the REG1 Anticoagulation System at the Transcatheter Cardiovascular Therapeutics (TCT) Symposium 2011
7. Karyopharm Therapeutics Closes $10 Million Series A2 Financing to Expand Planned Phase 1 Program of Oral Selective Inhibitors of Nuclear Export (SINE) for Cancer
8. Halozyme Therapeutics Announces Data From Two Phase 1 Studies of PEGPH20 Demonstrating Targeting of Hyaluronan in Tumor Stroma
9. United Therapeutics Corporation Reports Third Quarter 2011 Financial Results
10. Amsterdam Molecular Therapeutics Provides Operations Update & Strategic Review of Pipeline
11. Cell Therapeutics, Inc. (CTI) Reports Third Quarter Financial Results and Milestones
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... 2014 ViaDerma, Inc ... devoted to bringing new products to market, is ... ViaDerma has developed an innovative, patent-pending dual carrier ... transfer of pharmaceutical active ingredients to penetrate the ... localized therapy. The transdermal delivery method also overcomes ...
(Date:10/25/2014)... (PRWEB) October 24, 2014 This ... PHA, PBS, Starch Based Plastics, Regenerated Cellulose, PCL), ... Global Trends and Forecasts to 2019”, defines and ... analysis and forecast of its global volume and ... 54 Figures spread through 178 Slides and in-depth ...
(Date:10/25/2014)... 24, 2014 Oramed Pharmaceuticals Inc. ... focused on the development of oral drug delivery systems, ... will present at FireRock Capital,s Micro-Cap Conference. ... Conference ,Date: Tuesday, October 28, 2014 ,Time: 9:15am EST ... York City , About The ...
(Date:10/25/2014)... 24, 2014 ... has announced the addition of the  "The ... Other 2-D Nanomaterials "  report to their ... ,CNTs and graphene are the strongest, lightest ... with a performance-per-weight greater than any other ...
Breaking Biology Technology:ViaDerma, Inc. Announces Plans to Pursue Out-Licensing Partnerships in 2015 2ViaDerma, Inc. Announces Plans to Pursue Out-Licensing Partnerships in 2015 3Biodegradable Plastics Market Projected to $3,476.87 Million by 2019 - Report by MarketsandMarkets 2Biodegradable Plastics Market Projected to $3,476.87 Million by 2019 - Report by MarketsandMarkets 3Biodegradable Plastics Market Projected to $3,476.87 Million by 2019 - Report by MarketsandMarkets 4Oramed to Present at the FireRock Annual Micro-Cap Conference 2Oramed to Present at the FireRock Annual Micro-Cap Conference 3The Global Market for Carbon Nanotubes, Graphene and Other 2-D Nanomaterials 2The Global Market for Carbon Nanotubes, Graphene and Other 2-D Nanomaterials 3The Global Market for Carbon Nanotubes, Graphene and Other 2-D Nanomaterials 4
... , Key ... assay, , ... of one assay component to an SPA Imaging Bead in order to ... antibody enable the immobilization of rabbit secondary antibodies during the assay. The ...
... TE 70, TE 77, TE 70 PWR, TE 77 PWR , ... transfer results using low current and voltage with a minimal amount of buffer. ... with and without built-in power supplies to give maximum flexibility , ... from polyacrylamide gels in less than 1 h , ...
... Key words: ... LC-MS/MS • reversed-phase chromatography (RPC) • strong cation exchange (SCX) ... , ... brain tissue. The trypsin-digested tissue was separated by strong cation ...
Cached Biology Technology:Utilization of Donkey Anti-Rabbit PS SPA Imaging Beads in the quantitative measurement of cAMP in cells 2Utilization of Donkey Anti-Rabbit PS SPA Imaging Beads in the quantitative measurement of cAMP in cells 3Utilization of Donkey Anti-Rabbit PS SPA Imaging Beads in the quantitative measurement of cAMP in cells 4ECL Semi-dry Blotters 22D-LC analysis of phosphopeptides in brain tissue using Ettan MDLC and Finnigan LTQ 22D-LC analysis of phosphopeptides in brain tissue using Ettan MDLC and Finnigan LTQ 32D-LC analysis of phosphopeptides in brain tissue using Ettan MDLC and Finnigan LTQ 42D-LC analysis of phosphopeptides in brain tissue using Ettan MDLC and Finnigan LTQ 52D-LC analysis of phosphopeptides in brain tissue using Ettan MDLC and Finnigan LTQ 6
(Date:10/17/2014)... for the first time how bacteria can grow directly ... the opportunity to get tremendous insights into bacteria behavior ... discovered the bacterial growth in chronic lung infections among ... by the immune cells. The researchers discovered the immune ... bacteria, forcing the bacteria to switch to a much ...
(Date:10/16/2014)... conventional thinking on how the bowel lining develops and, ... bowel cancer starts. , The researchers produced evidence that ... ,crypts, that are a feature of the bowel lining, ... cancer development, a controversial finding as scientists are still ... imaging technologies, Dr Chin Wee Tan and Professor Tony ...
(Date:10/15/2014)... Oct. 15, 2014 Sandata Technologies, LLC, ... and community-based care, today announced it released a ... Santrax® Electronic Visit Verification™ Solution (EVV™)  for Quality ... home health company founded in 1996 and has ... The study details the challenges ...
Breaking Biology News(10 mins):Scientists opens black box on bacterial growth in cystic fibrosis lung infection 2Cryptic clues drive new theory of bowel cancer development 2Sandata Announces Case Study with Quality Care Services, Inc. 2
... Taiwan and Japan and led by University of Illinois scientists ... times more active in killing tumor cells than similar drugs ... this week in the Journal of the American Chemical ... of drugs called bisphosphonates. These compounds were originally developed to ...
... Researchers at the Tulane University School of Medicine, ... protease inhibitors (PIs), such as nelfinavir included in ... treatment of HIV-1 patients, induce deleterious effects on ... They report a significant decrease in the levels ...
... researcher has discovered dozens of species of jumping spiders that ... section of the evolutionary tree previously thought to be sparse. ... world except Antarctica. Capable of jumping 30 times their body ... households. They come in many shapes and sizes, some resembling ...
Cached Biology News:New drug agent knocks out multiple enzymes in cancer pathway 2HIV-1 protease inhibitor induced oxidative stress in pancreatic B-cells: thymoquinone protection 2New species of spiders discovered by UBC scientist in Papua New Guinea 2
Src cDNA Expression Kit (wild type)...
1M stock solution (238mg/ml)...
Homogenizing Solution, 18ml Proteinase K - [50ug/l] 75 l...
Request Info...
Biology Products: